In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

almost all patients progress to castration-resistant prostate cancer (CRPC). The understanding of the biology of CRPC and the evidence that CRPC still remains driven by androgen receptor signaling ...

Announcing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men.

They can now choose among 4 novel second-generation hormone therapies (the androgen receptor pathway inhibitors ... achieve the best outcomes from prostate cancer treatment—is still being ...

Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men. PrCa is marked by uncontrolled cellular growth that leads to abnormal enlargement of the prostate gland. The metastatic ...

Jan. 28, 2025 — The inherited mutated gene WNT9B, which functions normally in embryonic prostate development, increases risk of adult prostate cancer, according to a new ... Jan. 3, 2025 — In ...

In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients ...

For the study, scientists analysed data from 439 advanced prostate cancer samples and found higher levels of heat shock proteins were associated with more androgen receptor signalling, which ...

Evan Y. Yu, MD, discusses the design and objectives of the phase 3 PEACE 3 study, which evaluates the combination of enzalutamide (ENZA) and radium-223 (Ra-223) in androgen receptor pathway inhibitor ...